CD40 interacts directly with RAG1 and RAG2 in autoaggressive T cells and Fas prevents CD40-induced RAG expression

Cellular and Molecular Immunology

Volumn 10, Issue 6, 2013, Pages 483-489

  Vaitaitis, Gisela M ^a   Wagner, David H ^a  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

autoimmunity; CD40; Fas; RAG; T cell receptor

Indexed keywords

CD40 ANTIGEN; FAS ANTIGEN; KU ANTIGEN; RAG1 PROTEIN; RAG2 PROTEIN; T LYMPHOCYTE RECEPTOR;

ANIMAL CELL; ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; CELL NUCLEUS; CONTROLLED STUDY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD40; ANTIGENS, CD95; ANTIGENS, NUCLEAR; AUTOIMMUNITY; CELL NUCLEUS; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION; HOMEODOMAIN PROTEINS; MICE; MICE, INBRED NOD; PROTEIN BINDING; PROTEIN TRANSPORT; RECEPTORS, ANTIGEN, T-CELL, ALPHA-BETA; RNA, MESSENGER; T-LYMPHOCYTES; THYMOCYTES;

EID: 84888321980     PISSN: 16727681     EISSN: None     Source Type: Journal    
DOI: 10.1038/cmi.2013.24     Document Type: Article

References (49)

1. Leu TM, Schatz DG. rag-1 and rag-2 are components of a high-molecular-weight complex, and association of rag-2 with this complex is rag-1 dependent. Mol Cell Biol 1995; 15: 5657-5670.
2. Tonegawa S. Somatic generation of antibody diversity. Nature 1983; 302: 575-581.
3. McGargill MA, Derbinski JM, Hogquist KA. Receptor editing in developing T cells. Nat Immunol 2000; 1: 336-341.
4. 1 T cells. Immunity 1998; 9: 637-647. (Pubitemid 28557592)
5. McMahan CJ, Fink PJ. Receptor revisionin peripheralT cells creates a diverse V beta repertoire. J Immunol 2000; 165: 6902-6907. (Pubitemid 32001160)
6. 1 T lymphocytes. Proc Natl Acad Sci USA 2002; 13: 13.
7. Vaitaitis GM, Poulin M, Sanderson RJ, Haskins K, Wagner DH Jr. Cutting edge: CD40-induced expression of recombination activating gene (RAG) 1 and RAG2: a mechanism for the generation of autoaggressive T cells in the periphery. J Immunol 2003; 170: 3455-3459. (Pubitemid 36359210)
8. Zehn D, Bevan MJ, Fink PJ. Cutting edge: TCR revision affects predominantly Foxp3 cells and skews them toward the Th17 lineage. J Immunol 2007; 179: 5653-5657.
9. Cooper CJ, Orr MT, McMahan CJ. Fink PJ. T cell receptor revision does not solely target recent thymic emigrants. J Immunol 2003; 171: 226-233. (Pubitemid 36745292)
10. Cooper CJ, Turk GL, Sun M, Farr AG, Fink PJ. Cutting Edge: TCR revision occurs in germinal centers. J Immunol 2004; 173: 6532-6536. (Pubitemid 39541035)
11. Takase M, Kanagawa EM, Kanagawa O. Age-dependent TCR revision mediated by interaction between alphabeta TCR and self-antigens. J Immunol 2007; 179: 2163-2169.
12. Fink PJ, McMahan CJ. Lymphocytes rearrange, edit and revise their antigen receptors to be useful yet safe. Immunol Today 2000; 21: 561-566.
13. Hale JS, Ames KT, Boursalian TE, Fink PJ. Cutting Edge: Rag deletion in peripheral T cells blocks TCR revision. J Immunol 2010; 184: 5964-5968.
14. Wagner DH Jr. Re-shaping the T cell repertoire: TCR editing and TCR revision for good and for bad. Clin Immunol 2007; 123: 1-6. (Pubitemid 46415682)
15. Wagner DH Jr, Newell E, Sanderson RJ, Freed JH, Newell MK. Increased expression of CD40 on thymocytes and peripheral T cells in autoimmunity: a mechanism for acquiring changes in the peripheral T cell receptor repertoire. Int J Mol Med 1999; 4: 231-242.
16. Blish CA, Gallay BJ, Turk GL, Kline KM, Wheat W, Fink PJ. Chronic modulation of the TCR repertoire in the lymphoid periphery. J Immunol 1999; 162: 3131-3140. (Pubitemid 29313557)
17. Balasa B, Krahl T, Patstone G, Lee J, Tisch R, McDevitt HO et al. CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice. J Immunol 1997; 159: 4620-4627. (Pubitemid 127470625)
18. Durie FH, Fava RA, Foy TM, Aruffo A, Ledbetter JA, Noelle RJ. Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 1993; 261: 1328-1330. (Pubitemid 24081170)
19. Kobata T, Azuma M, Yagita H, Okumura K. Role of costimulatory molecules in autoimmunity. Rev Immunogenet 2000; 2: 74-80. (Pubitemid 30142485)
20. Munroe ME, Bishop GA. A costimulatory function for T cell CD40. J Immunol 2007; 178: 671-682. (Pubitemid 46095139)
21. Quezada SA, Eckert M, Adeyi OA, Schned AR, Noelle RJ, Burns CM. Distinct mechanisms of action of anti-CD154 in early versus late treatment of murine lupus nephritis. Arthritis Rheum 2003; 48: 2541-2554. (Pubitemid 37138671)
22. Toubi E, Shoenfeld Y. The role of CD40-CD154 interactions in autoim-munity and the benefit of disrupting this pathway. Autoimmunity 2004; 37: 457-464. (Pubitemid 40123415)
23. Vaitaitis GM, Wagner DH Jr. High distribution of CD40 and TRAF2 in Th40 T cell rafts leads to preferential survival of this auto-aggressive population in autoimmunity. PLoS ONE 2008; 3: e2076.
24. 1 auto-aggressive T cell expansion during insulin-dependent diabetes mellitus. Eur J Immunol 2004; 34: 1488-1497. (Pubitemid 39256029)
25. Wang X, Huang W, Mihara M, Sinha J, Davidson A. Mechanism of action of combined short-term CTLA4Ig and anti-CD40 ligand in murine systemic lupus erythematosus. J Immunol 2002; 168: 2046-2053. (Pubitemid 34135809)
26. Yu S, Medling B, Yagita H, Braley-Mullen H. Characteristics of inflammatory cells in spontaneous autoimmune thyroiditis of NOD. H-2h4 mice. J Autoimmun 2001; 16: 37-46. (Pubitemid 32174173)
27. Wagner DH Jr, Vaitaitis G, Sanderson R, Poulin M, Dobbs C, Haskins K. Expression of CD40 identifies a unique pathogenic T cell population in type 1 diabetes. Proc Natl Acad Sci USA 2002; 99: 3782-3787. (Pubitemid 34252183)
28. 1) T cells promotes diabetes. J Leukoc Biol 2008; 84: 431-439.
29. 1 T cells (TCD40) in human type 1 diabetes. Clin Immunol 2007; 124: 138-148. (Pubitemid 47059045)
30. 1 T cells. J Immunol 2010; 185: 6528-6534.
31. Hillion S, Dueymes M, Youinou P, Jamin C. IL-6 contributes to the expression of RAGs in human mature B cells. J Immunol 2007; 179: 6790-6798.
32. Heath AW, Wu WW, Howard MC. Monoclonal antibodies to murine CD40 define two distinct functional epitopes. Eur J Immunol 1994; 24: 1828-1834. (Pubitemid 24237553)
33. Rolink A, Melchers F, Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 1996; 5: 319-330. (Pubitemid 26366755)
34. Haskins K, Portas M, Bergman B, Lafferty K, Bradley B. Pancreatic islet-specific T-cell clones from nonobese diabetic mice. Proc Natl Acad Sci USA 1989; 86: 8000-8004. (Pubitemid 19265307)
35. Vaitaitis GM, Wagner DH Jr. CD40 glycoforms and TNF-receptors 1 and 2 in the formation of CD40 receptor(s) in autoimmunity. Mol Immunol 2010; 47: 2303-2313.
36. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
37. DiLorenzo TP, Graser RT, Ono T, Christianson GJ, Chapman HD, Roopenian DC et al. Major histocompatibility complex class I-restricted T cells are required for all but the end stages of diabetes development in nonobese diabetic mice and use a prevalent T cell receptor alpha chain gene rearrangement. Proc Natl Acad Sci USA 1998; 95: 12538-12543.
38. Gellert M. V(D)J recombination: RAG proteins, repair factors, and regulation. Annu Rev Biochem 2002; 71: 101-132. (Pubitemid 34800216)
39. Morio T, Hanissian SH, Bacharier LB, Teraoka H, Nonoyama S, Seki M et al. Ku in the cytoplasm associates with CD40 in human B cells and translocates into the nucleus following incubation with IL-4 and anti-CD40 mAb. Immunity 1999; 11: 339-348. (Pubitemid 29463242)
40. Lin-Lee YC, Pham LV, Tamayo AT, Yoshimura LC, Ford RJ. Nuclear localization in the biology of the CD40 receptor in normal and neoplastic human B lymphocytes. J Biol Chem 2006; 281: 18878-18887. (Pubitemid 44035547)
41. Datta SK. Production of pathogenic antibodies: cognate interactions between autoimmune T and B cells. Lupus 1998; 7: 591-596. (Pubitemid 29008224)
42. Stadinski BD, Delong T, Reisdorph N, Reisdorph R, Powell RL, Armstrong M et al. Chromogranin A is an autoantigen in type 1 diabetes. Nat Immunol 2010; 11: 225-231.
43. Hutchings P, Cooke A. Protection from insulin dependent diabetes mellitus afforded by insulin antigens in incomplete Freund's adjuvant depends on route of administration. J Autoimmun 1998; 11: 127-130. (Pubitemid 28273008)
44. Nakayama M, Babaya N, Miao D, Gianani R, Liu E, Elliott JF et al. Long-term prevention of diabetes and marked suppression of insulin autoantibodies and insulitis in mice lacking native insulin B9-23 sequence. Ann NY Acad Sci 2006; 1079: 122-129. (Pubitemid 44968711)
45. 1 T cells intype 1 diabetes in the nonobese diabetic (NOD) mouse. Proc Natl Acad Sci USA 2001; 108: 16729-16734.
46. Skarstrand H, Lernmark A, Vaziri-Sani F. Antigenicity and epitope specificity of ZnT8 autoantibodies in type 1 diabetes. Scand J Immunol 2013; 77: 21-29.
47. Hawkes CJ, Schloot NC, Marks J, Willemen SJ, Drijfhout JW, Mayer EK et al. T-cell lines reactive to an immunodominant epitope of the tyrosine phosphatase-like autoantigen IA-2 in type 1 diabetes. Diabetes 2000; 49: 356-366. (Pubitemid 30131780)
48. Abulafia-Lapid R, Elias D, Raz I, Keren-Zur Y, Atlan H, Cohen IR. T cell proliferative responses of type 1 diabetes patients and healthy individuals to human hsp60 and its peptides. J Autoimmun 1999; 12: 121-129. (Pubitemid 29130589)
49. Baker RL, Wagner DH Jr, Haskins K. CD40 on NOD CD4 T cells contributes to their activation and pathogenicity. J Autoimmun 2008; 31: 385-392.